Company intelligence / Profile preview

Enzymatica

Ownership: Private
Employees: ~21
Development stage: Commercial

Overview

Enzymatica’s lead product ColdZyme® mouth spray has demonstrated in several independent clinical studies that it can reduce the duration and severity of common cold symptoms by lowering viral load in the upper respiratory tract. Recent peer-reviewed publications confirm efficacy and high customer satisfaction; over nine out of ten users intend to repurchase.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: ProteinDevice
Industry: Biotech

Drug pipeline

2 assets

ColdZyme

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Not specifically named in public sources; company strategy focuses on global expansion via established partners/distributors

Beyond the preview

Go deeper on Enzymatica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enzymatica.

Explore the full profile